{"product_id":"biib-bcg-matrix","title":"(BIIB) Biogen Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Biogen Inc. BCG Matrix helps you see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs, making it useful for strategy, portfolio review, and investment analysis. The content on this page is a real preview of the actual report, so you can review the format and sample insights before buying. Purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLEQEMBI, early Alzheimer’s antibody\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLEQEMBI is Biogen’s key growth launch with Eisai, now approved in the U.S., Japan and China for early Alzheimer’s. The addressable U.S. market alone is about 6.9 million people age 65+, and it keeps expanding as diagnosis and biomarker testing improve. If uptake holds, LEQEMBI has the clearest path to a multibillion-dollar long-term franchise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQALSODY, SOD1-ALS treatment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQALSODY is the first approved therapy for SOD1-ALS, a rare group that accounts for about 2% of ALS cases. Biogen can still defend share because there is no direct like-for-like rival today, and its medical edge stays strong in a high-unmet-need niche. In Biogen's 2025 reporting, it remained an early but strategic growth asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZURZUVAE, postpartum depression launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZURZUVAE gives Biogen entry into postpartum depression, a U.S. market tied to about 1 in 8 mothers after birth. It sits in a growing neuropsychiatry niche with room to expand, so it can act like a Star if uptake holds. Value depends on faster diagnosis, payer access, and more prescriber comfort with a 14-day oral course.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBENEPALI, etanercept biosimilar\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBENEPALI, the etanercept biosimilar, stays a star in Biogen Inc.’s biosimilar mix because it holds strong share in Europe, where payers keep steering use toward lower-cost anti-TNF options. That makes it a high-share, high-growth BCG fit, even as pricing pressure stays tight.\u003c\/p\u003e\n\u003cp\u003eBiogen Inc.’s biosimilar base is still a real growth engine, and BENEPALI helps defend that spot through broad substitution and payer-led switching in key EU markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStrong Europe share\u003c\/li\u003e\n\u003cli\u003ePayer-driven switch to biosimilars\u003c\/li\u003e\n\u003cli\u003eHigh-share BCG star\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIMRALDI, adalimumab biosimilar\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIMRALDI sits in a big adalimumab biosimilar market still expanding after Humira lost US exclusivity in 2023 and EU erosion kept pushing price cuts. AbbVie’s Humira still posted about $9.3 billion in 2024 sales, showing the scale of switching pools. Biogen can use its commercial reach to win payer contracts and drive volume.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBig market, strong switch demand\u003c\/li\u003e\n\u003cli\u003ePrice cuts keep adoption high\u003c\/li\u003e\n\u003cli\u003eBiogen scale supports access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiogen’s Growth Drivers: LEQEMBI Leads the Way\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBiogen Inc.’s Stars are led by LEQEMBI, with U.S., Japan, and China approvals and a U.S. addressable market of about 6.9 million people age 65+. QALSODY keeps a first-mover edge in SOD1-ALS, a rare group of about 2% of ALS cases. ZURZUVAE adds a growing postpartum depression niche, while BENEPALI and IMRALDI support Biogen’s biosimilar growth in Europe.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStar case\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLEQEMBI\u003c\/td\u003e\n\u003ctd\u003eLarge, expanding Alzheimer’s market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQALSODY\u003c\/td\u003e\n\u003ctd\u003eFirst-in-class SOD1-ALS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZURZUVAE\u003c\/td\u003e\n\u003ctd\u003eGrowing postpartum depression use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBENEPALI\/IMRALDI\u003c\/td\u003e\n\u003ctd\u003eEU biosimilar share and switching\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBiogen’s BCG Matrix maps its portfolio to guide invest, hold, or divest choices across Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page Biogen Inc. BCG Matrix to quickly spot each unit’s quadrant and simplify portfolio decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eSupports confidence in Biogen Inc. decisions by showing credible, traceable sources behind the key assumptions and numbers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTYSABRI, long-running MS franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTYSABRI is a classic cash cow for Biogen Inc.: a mature MS brand with durable demand and low incremental launch spend. In Biogen Inc.’s 2025 filings, it still ranked among the company’s core revenue products, backed by a long track record of more than $1 billion in annual sales in prior years. MS growth is limited, but the franchise keeps strong share in a well-known indication and continues to throw off cash. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSPINRAZA, SMA market leader\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSPINRAZA is Biogen Inc.'s established SMA leader and a classic cash cow: despite a mature market, it still has a large installed base, strong brand recognition, and durable demand. Biogen has said SPINRAZA has generated over $1 billion in annual sales in recent years, showing its ongoing cash power even as competition rises. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRITUXAN, mature anti-CD20 brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRITUXAN is a mature anti-CD20 brand tied to long-used hematology and rheumatology indications, so it still throws off steady cash for Biogen Inc. Roche reported CHF 6.49 billion in 2024 sales for MabThera\/Rituxan, a sign of large but low-growth demand. With decades of clinical use and broad physician familiarity, it fits the cash cow profile: high share, slow growth, dependable cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRITUXAN HYCELA, subcutaneous oncology product\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRITUXAN HYCELA is a mature subcutaneous oncology product with a fixed 1,400 mg rituximab plus 23,400 units hyaluronidase dose, used in a narrow, established niche after IV rituximab induction. It is supported by entrenched prescribing habits, not fast volume growth, so the role is mainly cash extraction. The product fits a Cash Cow slot because the market is stable and switching costs are high.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFixed-dose, mature niche product\u003c\/li\u003e\n\u003cli\u003eDriven by repeat prescribing patterns\u003c\/li\u003e\n\u003cli\u003eLow growth, steady cash generation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGAZYVA, CLL and follicular lymphoma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGAZYVA fits a Cash Cow profile: CLL and follicular lymphoma are mature, recurring-use markets, not a fresh launch wave. CLL is the most common adult leukemia, and follicular lymphoma makes up about 20% of non-Hodgkin lymphoma cases, so demand stays steady. If Biogen keeps selling costs lean, this asset can keep generating cash.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable, repeat oncology demand\u003c\/li\u003e\n\u003cli\u003eMature market, low growth\u003c\/li\u003e\n\u003cli\u003eCash stays strong if costs stay tight\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiogen’s Cash Cows Keep the Revenue Engine Running\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBiogen Inc.'s cash cows are mature brands with steady demand and low launch spend. TYSABRI and SPINRAZA still anchor cash flow, each with over $1 billion in annual sales in recent years.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTYSABRI\u003c\/td\u003e\n\u003ctd\u003eCash cow\u003c\/td\u003e\n\u003ctd\u003eHigh share, slow growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSPINRAZA\u003c\/td\u003e\n\u003ctd\u003eCash cow\u003c\/td\u003e\n\u003ctd\u003eInstalled base, repeat use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eRITUXAN and GAZYVA add stable, recurring revenue from mature oncology use.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eBiogen Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Biogen Inc. BCG Matrix preview you see is the exact same document you’ll receive after purchase. No mockups, no demo pages—just the full, ready-to-use report. Once purchased, it’s instantly available for your own analysis, editing, or presentation. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTECFIDERA, generic-pressured MS brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTECFIDERA is a Dogs asset for Biogen Inc. because its U.S. exclusivity ended in 2020, and generics quickly crushed the franchise. Biogen reported TECFIDERA revenue at about $0.3B in 2024, far below its peak, showing the steep loss of share and growth. It is now a low-return legacy MS brand with weak pricing power and limited strategic value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAVONEX, older interferon therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAVONEX, launched in 1996, is an aging multiple sclerosis brand with fading relevance in Biogen Inc.'s portfolio. Newer therapies have taken share over time, so it sits firmly in the Dogs box: low growth, low share, and limited strategic upside. Its sales base is now a small, shrinking part of the MS business, which supports a harvest-or-exit view.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePLEGRIDY, declining interferon option\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePLEGRIDY stays stuck in the crowded interferon MS class, so Biogen gets little growth lift from it. The brand looks more like a maintenance asset than a driver, with low momentum and heavy competition from higher-efficacy MS options. In BCG terms, it fits a Dog: weak share, weak growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFAMPYRA, narrow MS supportive treatment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFAMPYRA is a narrow MS add-on for walking problems, with a 10 mg twice-daily dose and a short trial period to find responders. That limits its reach, so the addressable market stays small and growth is slow versus Biogen Inc.'s larger MS and rare-disease franchises.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSymptomatic, not disease-modifying\u003c\/li\u003e\n\u003cli\u003eSmall responder pool\u003c\/li\u003e\n\u003cli\u003eLow strategic momentum\u003c\/li\u003e\n\u003cli\u003eFits Dogs in the BCG Matrix\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eADUHELM, discontinued Alzheimer’s asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eADUHELM is a clear dog for Biogen Inc. It was voluntarily discontinued in January 2024 after failing to build durable share, and it never became a steady growth engine. Its fast fade and controversy made it a commercial and reputational drag, not a platform asset.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDiscontinued in January 2024\u003c\/li\u003e\n\u003cli\u003eNo durable market share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiogen’s Dogs: Legacy assets fading under generic and market pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBiogen Inc.’s Dogs are legacy, low-growth assets with weak share and little strategic lift. TECFIDERA fell to about $0.3B in 2024 after generic erosion, while AVONEX and PLEGRIDY stayed trapped in mature interferon MS markets. FAMPYRA remained niche, and ADUHELM was discontinued in January 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eDog signal\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTECFIDERA\u003c\/td\u003e\n\u003ctd\u003eGeneric hit\u003c\/td\u003e\n\u003ctd\u003e~$0.3B 2024 sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eADUHELM\u003c\/td\u003e\n\u003ctd\u003eExited\u003c\/td\u003e\n\u003ctd\u003eStopped Jan 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBIIB080, tau-targeting Alzheimer’s candidate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBIIB080 targets tau, a key driver in Alzheimer’s, which affects about 7.2 million Americans in 2025 and creates a huge unmet need. Biogen’s asset is still early, so it has not built market share yet and still needs clinical proof and physician adoption. That makes it a clear question mark: high upside, but success is not established.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBIIB059, lupus and immune-neurology candidate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBIIB059 sits in a tough lupus\/immune-neurology niche with high unmet need: lupus affects about 5 million people worldwide, and treatment response is still uneven. It is a classic Question Mark in Biogen Inc. BCG Matrix Analysis because the asset can be meaningful, but it is still unproven and needs clear clinical edge.\u003c\/p\u003e\n\u003cp\u003eSuccess will depend on showing better efficacy and safety than current immunology options, plus winning payer access in a market where biologic pricing is tightly managed. Until late-stage data and regulatory traction are clear, BIIB059 remains high-potential but not yet a cash generator for Company Name.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDAPIROLIZUMAB PEGOL, lupus program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDapirolizumab pegol is a Question Mark for Biogen Inc.'s lupus bet because it targets systemic lupus erythematosus, a disease affecting about 5 million people worldwide. The market is attractive, but it is crowded and hard to win, with only a few approved lupus drugs and high trial failure risk. It needs heavy R\u0026amp;D spend and clear late-stage data before it can shift from a cash drain to a leader.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBIIB122, Parkinson’s disease program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBIIB122 is a Parkinson’s disease asset in Biogen Inc.’s pipeline, so it has no current market share yet. That fits a question mark: the addressable market is large, with Parkinson’s affecting more than 10 million people worldwide, but value depends on clinical success and launch timing.\u003c\/p\u003e\n\u003cp\u003eBiogen Inc. is still investing in development, so BIIB122 can become meaningful only if it proves strong efficacy and safety in late-stage trials.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge market, zero current share\u003c\/li\u003e\n\u003cli\u003eHigh upside, high trial risk\u003c\/li\u003e\n\u003cli\u003eQuestion mark in BCG terms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBIIB131, acute neurological events program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBIIB131 is a Question Mark in Biogen Inc. because it targets acute neurological events in a high-need CNS space, but it has no market share yet and no disclosed product revenue. If clinical data are strong, the upside can be large; if not, the program stays a cash drain under Biogen Inc.’s R\u0026amp;D spend. For now, it is a high-risk bet, not a proven asset.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNo sales, no share\u003c\/li\u003e\n\u003cli\u003eHigh unmet CNS need\u003c\/li\u003e\n\u003cli\u003eUpside depends on data\u003c\/li\u003e\n\u003cli\u003eStill consumes cash\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiogen’s Big Bets: Zero Sales, Huge 2025 Potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBiogen Inc.’s Question Marks are BIIB080, BIIB059, dapirolizumab pegol, BIIB122, and BIIB131: all have zero current sales, but target huge 2025 markets like Alzheimer’s, lupus, and Parkinson’s.\u003c\/p\u003e\n\u003cp\u003eThey can only move up if late-stage data beat today’s standards and win payer access; until then, they stay R\u0026amp;D cash uses, not cash generators.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025 market\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBIIB080\u003c\/td\u003e\n\u003ctd\u003e7.2M US Alzheimer’s\u003c\/td\u003e\n\u003ctd\u003eUnproven\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBIIB122\u003c\/td\u003e\n\u003ctd\u003e10M+ Parkinson’s\u003c\/td\u003e\n\u003ctd\u003eZero share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191781531913,"sku":"biib-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/biib-bcg-matrix.webp?v=1783678442","url":"https:\/\/dcfanalyst.com\/products\/biib-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}